What have we learned in dermatology from the biologic therapies? - Monoclonal Antibodies

What have we learned in dermatology from the biologic therapies?
March 2006
Brian J. Nickoloff and Seth R. Stevens
Journal of the American Academy of Dermatology
Abstract
Recent advances in our basic understanding of immunology, specifically the roles of various cell types involved in immune response and the action of cytokines they produce, has radically changed our understanding of the origin of inflammatory dermatoses, and other autoimmune diseases. Broadened comprehension of the immune response on a molecular level has facilitated the development of biologic therapeutics for the treatment of psoriasis, atopic dermatosis, and other inflammatory conditions. However, despite major advances in development and use of targeted biologics for controlling autoimmune disease, effective cures for these conditions remain to be developed and genetic determinants of predisposition to such diseases remain to be identified. Here, we review the history of our understanding of inflammatory dermatoses, traditional and new treatment approaches, and future directions for research and therapy in this area.
Abbreviations: Ab, antibody; AD, atopic dermatitis; APC, dendritic antigen-presenting cell; DC, dendritic cell; IFN, interferon; Ig, immunoglobulin; IL, interleukin; LFA, lymphocyte function-associated antigen; mAb, monoclonal antibody; NK, natural killer; PsO, psoriasis; TH1, type 1 helper T cell; TH2, type 2 helper T cell; TNF, tumor necrosis factor
A subscription is required to view the complete article.